Aptahem AB (XSAT:APTA) EBITDA Margin %: 0.00% (As of Mar. 2026)


XSAT:APTA Aptahem AB XSAT:APTA
30 GF Score
Price kr0.50
! 2 Warning Signs
View Full Analysis

What is Aptahem AB EBITDA Margin %?

Aptahem AB XSAT:APTA -9.09% 30 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates XSAT:APTA with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, Aptahem AB ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Aptahem AB's EBITDA for the three months ended in Mar. 2026 was kr-1.33 Mil. Aptahem AB's Revenue for the three months ended in Mar. 2026 was kr0.00 Mil. Therefore, Aptahem AB's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Aptahem AB  (XSAT:APTA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Aptahem AB EBITDA Margin % Related Terms

Aptahem AB EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Aptahem AB's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aptahem AB EBITDA Margin % Chart

Aptahem AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Aptahem AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XSAT:APTA vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Aptahem AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptahem AB EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptahem AB's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Aptahem AB's EBITDA Margin % falls into.


XSAT:APTA
30GF Score
Aptahem AB XSAT:APTA
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aptahem AB EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Aptahem AB's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-6.252/0
= %

Aptahem AB's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.332/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Aptahem AB (XSAT:APTA) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aptahem AB and its competitors. According to the industry distribution chart, Aptahem AB ranks #999999 out of 944 companies in the Biotechnology industry.
Is Aptahem AB's EBITDA Margin % too high?
Aptahem AB's current EBITDA Margin % is 0.00%. Based on the distribution chart, Aptahem AB ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aptahem AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aptahem AB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aptahem AB ranks #999999 out of 944 companies for EBITDA Margin %. This places Aptahem AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aptahem AB and its competitors. Aptahem AB's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptahem AB stock overvalued right now?
Aptahem AB (XSAT:APTA) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Aptahem AB's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Aptahem AB (XSAT:APTA), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aptahem AB Business Description

Address Norra Vallgatan 58, Malmo, SWE, 211 22
Aptahem AB develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's main candidate Apta-1 is developed as an emergency medicine intended to prevent the occurrence of life-threatening organ and tissue damage in patients suffering from sepsis.
30GF Score

Get the complete analysis for XSAT:APTA

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.50
Price